title: Low-dose recombinant canine interferon-gamma for treatment of canine atopic dermatitis: an open randomized comparative trial of two doses.
abstract: The purpose of this study was to investigate the minimum effective dose of recombinant canine interferon-gamma (rCaIFN-gamma) for the treatment of dogs with atopic dermatitis (AD). Thirty-four dogs with AD from 17 animal hospitals in Japan were administered half or one-fifth of the approved rCaIFN-gamma dose of 10 000 units/kg, three times a week for 4 weeks, followed by once weekly for an additional 4 weeks. Pruritus, excoriation, erythema and alopecia were evaluated and scored by the investigators on weeks 2, 4, 6, 8 and 12. The efficacy rate (number of excellent cases + number of good cases/total number of cases) at week 8 in the 2000 units/kg group was 36.4% for pruritus, 36.4% for excoriation, 45.5% for erythema and 36.4% for alopecia. In contrast, in the 5000 units/kg group, the efficacy rate was 64.3% for pruritus, 57.1% for excoriation, 78.6% for erythema and 78.6% for alopecia. The efficacy rate of the 5000 units/kg group was high for all signs evaluated and comparable to that of the 10 000 units/kg group reported in a previous study. The results of this study showed that 2000 units/kg of rCaIFN-gamma is less effective than 5000 units/kg to treat dogs with AD, and the efficacy of the 5000 units/kg dose is comparable to that of 10 000 units/kg at week 8.
authors.affiliation: Sanyo Animal Medical Center, 357-1, Koumoto, Akaiwa, Okayama 709-0821, Japan. yasu9244-vet@au8.mopera.ne.jp
authors.forename: Kuniyoshi
authors.initials: K
authors.lastname: Yasukawa
authors.forename: Shiori
authors.initials: S
authors.lastname: Saito
authors.forename: Takuya
authors.initials: T
authors.lastname: Kubo
authors.forename: Yuya
authors.initials: Y
authors.lastname: Shibasaki
authors.forename: Kayo
authors.initials: K
authors.lastname: Yamaoka
authors.forename: Hisae
authors.initials: H
authors.lastname: Hachimura
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kuyama
authors.forename: Akiteru
authors.initials: A
authors.lastname: Amimoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kumata
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kitahara
authors.forename: Masahiko
authors.initials: M
authors.lastname: Takenaka
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Matsumura
authors.forename: Takehiro
authors.initials: T
authors.lastname: Uno
authors.forename: Tomiya
authors.initials: T
authors.lastname: Uchino
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Takehara
authors.forename: Kouji
authors.initials: K
authors.lastname: Nishida
authors.forename: Michiyo
authors.initials: M
authors.lastname: Kadoya
authors.forename: Masafumi
authors.initials: M
authors.lastname: Sato
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kato
authors.forename: Kanako
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Satoshi
authors.initials: S
authors.lastname: Saito
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Shimoda
mesh_terms: D000818:Animals; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D007371:Interferon-gamma / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D007371:Interferon-gamma